Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors

Phase 2

Completed

Conditions: Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor
Teratoma

First Posted Date: 2006-03-13

Last Posted Date: 2013-08-26

Lead Sponsor: Medical Research Council

Target Recruit Count: 88

Registration Number: NCT00301782

Locations: 🇬🇧
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
🇬🇧
Gloucestershire Oncology Centre at Cheltenham General Hospital, Cheltenham, England, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom

and more 17 locations

Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: Cetuximab
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Conventional Surgery
Radiation: Radiation Therapy

First Posted Date: 2006-03-10

Last Posted Date: 2013-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00301028

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: docetaxel
Biological: Trastuzumab
Drug: doxorubicin hydrochloride
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-02-24

Last Posted Date: 2024-01-05

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 121

Registration Number: NCT00295893

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Tarceva
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2006-02-22

Last Posted Date: 2012-08-09

Lead Sponsor: OSI Pharmaceuticals

Target Recruit Count: 143

Registration Number: NCT00294762

Locations: 🇺🇸
Alegent Healthcare, Omaha, Nebraska, United States
🇺🇸
Hematology-Oncology Associates, SJ, PA - Virtua Health, Mount Holly, New Jersey, United States
🇺🇸
Boston Baskin Cancer Groupd/b/a U. of Tennessee Cancer Inst., Memphis, Tennessee, United States

and more 40 locations

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell Lung

First Posted Date: 2006-02-22

Last Posted Date: 2010-06-28

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 50

Registration Number: NCT00294931

Locations: 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 1 locations

Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain

Phase 3

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-02-17

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 500

Registration Number: NCT00293358

Locations: 🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland
🇬🇧
Institute of Child Health at University of Bristol, Bristol, England, United Kingdom
🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom

and more 17 locations

Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Phase 2

Terminated

Conditions: Lung Cancer

First Posted Date: 2006-02-17

Last Posted Date: 2011-02-09

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 1

Registration Number: NCT00293332

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Phase 1

Conditions: Central Nervous System Lymphoma

Interventions: Drug: Carboplatin
Drug: Mannitol
Drug: Methotrexate
Other: Quality-of-Life Assessment
Biological: Rituximab
Drug: Sodium Thiosulfate

First Posted Date: 2006-02-17

Last Posted Date: 2021-09-22

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 81

Registration Number: NCT00293475

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States

and more 1 locations

Phase II Study of ZD6474 in Advanced NSCLC

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: ZD6474
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-02-13

Last Posted Date: 2016-05-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00290537

Locations: 🇺🇸
University of Texas M.D.Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma

Not Applicable

Conditions: Neuroblastoma

First Posted Date: 2006-02-07

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 120

Registration Number: NCT00287950

Locations: 🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy